 | • レポートコード：MRC308GR11636 • 出版社/出版日：GlobalInfoResearch / 2023年8月12日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界のがん免疫療法薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のがん免疫療法薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– がん免疫療法薬の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
がん免疫療法薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・PD-1阻害剤、PDL-1阻害剤、T細胞刺激剤、CTLA抗体
用途別セグメント
・病院、診療所、その他
主要な市場プレーヤー
・Autolus Therapeutics plc、BeiGene、bluebird bio, Inc.、Bristol-Myers Squibb、Celgene Corporation、AstraZeneca plc、Gilead Sciences, Inc.、Incyte Corporation、Jiangsu Hengrui Medicine、Juno Pharmaceuticals Pty Ltd.、Medimmune, LLC、Merck & Co., Inc.、Novartis AG、Pfizer, Inc.、Roche Holding AG
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、がん免疫療法薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要ながん免疫療法薬メーカーの企業概要、2019年～2022年までのがん免疫療法薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要ながん免疫療法薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別がん免疫療法薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのがん免疫療法薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのがん免疫療法薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびがん免疫療法薬の産業チェーンを掲載しています。
・第14、15章では、がん免疫療法薬の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– がん免疫療法薬の概要
– 種類別分析（2018年vs2022年vs2029年）：PD-1阻害剤、PDL-1阻害剤、T細胞刺激剤、CTLA抗体
– 用途別分析（2018年vs2022年vs2029年）：病院、診療所、その他
– 世界のがん免疫療法薬市場規模・予測
– 世界のがん免疫療法薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Autolus Therapeutics plc、BeiGene、bluebird bio, Inc.、Bristol-Myers Squibb、Celgene Corporation、AstraZeneca plc、Gilead Sciences, Inc.、Incyte Corporation、Jiangsu Hengrui Medicine、Juno Pharmaceuticals Pty Ltd.、Medimmune, LLC、Merck & Co., Inc.、Novartis AG、Pfizer, Inc.、Roche Holding AG
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：PD-1阻害剤、PDL-1阻害剤、T細胞刺激剤、CTLA抗体
・用途別分析2018年-2029年：病院、診療所、その他
・がん免疫療法薬の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・がん免疫療法薬のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・がん免疫療法薬のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・がん免疫療法薬の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・がん免疫療法薬の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapy Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 PD-1 Inhibitor
1.3.3 PDL-1 Inhibitor
1.3.4 T-Cell Stimulant
1.3.5 CTLA Antibody
1.4 Market Analysis by Application
1.4.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Cancer Immunotherapy Drug Market Size & Forecast
1.5.1 Global Cancer Immunotherapy Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Cancer Immunotherapy Drug Sales Quantity (2018-2029)
1.5.3 Global Cancer Immunotherapy Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Autolus Therapeutics plc
2.1.1 Autolus Therapeutics plc Details
2.1.2 Autolus Therapeutics plc Major Business
2.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
2.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Autolus Therapeutics plc Recent Developments/Updates
2.2 BeiGene
2.2.1 BeiGene Details
2.2.2 BeiGene Major Business
2.2.3 BeiGene Cancer Immunotherapy Drug Product and Services
2.2.4 BeiGene Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 BeiGene Recent Developments/Updates
2.3 bluebird bio, Inc.
2.3.1 bluebird bio, Inc. Details
2.3.2 bluebird bio, Inc. Major Business
2.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
2.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 bluebird bio, Inc. Recent Developments/Updates
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
2.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol-Myers Squibb Recent Developments/Updates
2.5 Celgene Corporation
2.5.1 Celgene Corporation Details
2.5.2 Celgene Corporation Major Business
2.5.3 Celgene Corporation Cancer Immunotherapy Drug Product and Services
2.5.4 Celgene Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Celgene Corporation Recent Developments/Updates
2.6 AstraZeneca plc
2.6.1 AstraZeneca plc Details
2.6.2 AstraZeneca plc Major Business
2.6.3 AstraZeneca plc Cancer Immunotherapy Drug Product and Services
2.6.4 AstraZeneca plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AstraZeneca plc Recent Developments/Updates
2.7 Gilead Sciences, Inc.
2.7.1 Gilead Sciences, Inc. Details
2.7.2 Gilead Sciences, Inc. Major Business
2.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
2.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Gilead Sciences, Inc. Recent Developments/Updates
2.8 Incyte Corporation
2.8.1 Incyte Corporation Details
2.8.2 Incyte Corporation Major Business
2.8.3 Incyte Corporation Cancer Immunotherapy Drug Product and Services
2.8.4 Incyte Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Incyte Corporation Recent Developments/Updates
2.9 Jiangsu Hengrui Medicine
2.9.1 Jiangsu Hengrui Medicine Details
2.9.2 Jiangsu Hengrui Medicine Major Business
2.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
2.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
2.10 Juno Pharmaceuticals Pty Ltd.
2.10.1 Juno Pharmaceuticals Pty Ltd. Details
2.10.2 Juno Pharmaceuticals Pty Ltd. Major Business
2.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
2.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
2.11 Medimmune, LLC
2.11.1 Medimmune, LLC Details
2.11.2 Medimmune, LLC Major Business
2.11.3 Medimmune, LLC Cancer Immunotherapy Drug Product and Services
2.11.4 Medimmune, LLC Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Medimmune, LLC Recent Developments/Updates
2.12 Merck & Co., Inc.
2.12.1 Merck & Co., Inc. Details
2.12.2 Merck & Co., Inc. Major Business
2.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
2.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Merck & Co., Inc. Recent Developments/Updates
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Cancer Immunotherapy Drug Product and Services
2.13.4 Novartis AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Novartis AG Recent Developments/Updates
2.14 Pfizer, Inc.
2.14.1 Pfizer, Inc. Details
2.14.2 Pfizer, Inc. Major Business
2.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
2.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Pfizer, Inc. Recent Developments/Updates
2.15 Roche Holding AG
2.15.1 Roche Holding AG Details
2.15.2 Roche Holding AG Major Business
2.15.3 Roche Holding AG Cancer Immunotherapy Drug Product and Services
2.15.4 Roche Holding AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Roche Holding AG Recent Developments/Updates
3 Competitive Environment: Cancer Immunotherapy Drug by Manufacturer
3.1 Global Cancer Immunotherapy Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Cancer Immunotherapy Drug Revenue by Manufacturer (2018-2023)
3.3 Global Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Cancer Immunotherapy Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Cancer Immunotherapy Drug Manufacturer Market Share in 2022
3.5 Cancer Immunotherapy Drug Market: Overall Company Footprint Analysis
3.5.1 Cancer Immunotherapy Drug Market: Region Footprint
3.5.2 Cancer Immunotherapy Drug Market: Company Product Type Footprint
3.5.3 Cancer Immunotherapy Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cancer Immunotherapy Drug Market Size by Region
4.1.1 Global Cancer Immunotherapy Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Cancer Immunotherapy Drug Consumption Value by Region (2018-2029)
4.1.3 Global Cancer Immunotherapy Drug Average Price by Region (2018-2029)
4.2 North America Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.3 Europe Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.5 South America Cancer Immunotherapy Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Cancer Immunotherapy Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
5.2 Global Cancer Immunotherapy Drug Consumption Value by Type (2018-2029)
5.3 Global Cancer Immunotherapy Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
6.2 Global Cancer Immunotherapy Drug Consumption Value by Application (2018-2029)
6.3 Global Cancer Immunotherapy Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
7.2 North America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
7.3 North America Cancer Immunotherapy Drug Market Size by Country
7.3.1 North America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
8.2 Europe Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
8.3 Europe Cancer Immunotherapy Drug Market Size by Country
8.3.1 Europe Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Cancer Immunotherapy Drug Market Size by Region
9.3.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
10.2 South America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
10.3 South America Cancer Immunotherapy Drug Market Size by Country
10.3.1 South America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Cancer Immunotherapy Drug Market Size by Country
11.3.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Cancer Immunotherapy Drug Market Drivers
12.2 Cancer Immunotherapy Drug Market Restraints
12.3 Cancer Immunotherapy Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Cancer Immunotherapy Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cancer Immunotherapy Drug
13.3 Cancer Immunotherapy Drug Production Process
13.4 Cancer Immunotherapy Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cancer Immunotherapy Drug Typical Distributors
14.3 Cancer Immunotherapy Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Cancer Immunotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cancer Immunotherapy Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Autolus Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 4. Autolus Therapeutics plc Major Business
Table 5. Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
Table 6. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Autolus Therapeutics plc Recent Developments/Updates
Table 8. BeiGene Basic Information, Manufacturing Base and Competitors
Table 9. BeiGene Major Business
Table 10. BeiGene Cancer Immunotherapy Drug Product and Services
Table 11. BeiGene Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. BeiGene Recent Developments/Updates
Table 13. bluebird bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. bluebird bio, Inc. Major Business
Table 15. bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
Table 16. bluebird bio, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. bluebird bio, Inc. Recent Developments/Updates
Table 18. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
Table 21. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Bristol-Myers Squibb Recent Developments/Updates
Table 23. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 24. Celgene Corporation Major Business
Table 25. Celgene Corporation Cancer Immunotherapy Drug Product and Services
Table 26. Celgene Corporation Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Celgene Corporation Recent Developments/Updates
Table 28. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 29. AstraZeneca plc Major Business
Table 30. AstraZeneca plc Cancer Immunotherapy Drug Product and Services
Table 31. AstraZeneca plc Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. AstraZeneca plc Recent Developments/Updates
Table 33. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Gilead Sciences, Inc. Major Business
Table 35. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
Table 36. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Gilead Sciences, Inc. Recent Developments/Updates
Table 38. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 39. Incyte Corporation Major Business
Table 40. Incyte Corporation Cancer Immunotherapy Drug Product and Services
Table 41. Incyte Corporation Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Incyte Corporation Recent Developments/Updates
Table 43. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 44. Jiangsu Hengrui Medicine Major Business
Table 45. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
Table 46. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 48. Juno Pharmaceuticals Pty Ltd. Basic Information, Manufacturing Base and Competitors
Table 49. Juno Pharmaceuticals Pty Ltd. Major Business
Table 50. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
Table 51. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
Table 53. Medimmune, LLC Basic Information, Manufacturing Base and Competitors
Table 54. Medimmune, LLC Major Business
Table 55. Medimmune, LLC Cancer Immunotherapy Drug Product and Services
Table 56. Medimmune, LLC Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Medimmune, LLC Recent Developments/Updates
Table 58. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 59. Merck & Co., Inc. Major Business
Table 60. Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
Table 61. Merck & Co., Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Merck & Co., Inc. Recent Developments/Updates
Table 63. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 64. Novartis AG Major Business
Table 65. Novartis AG Cancer Immunotherapy Drug Product and Services
Table 66. Novartis AG Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Novartis AG Recent Developments/Updates
Table 68. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 69. Pfizer, Inc. Major Business
Table 70. Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
Table 71. Pfizer, Inc. Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Pfizer, Inc. Recent Developments/Updates
Table 73. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 74. Roche Holding AG Major Business
Table 75. Roche Holding AG Cancer Immunotherapy Drug Product and Services
Table 76. Roche Holding AG Cancer Immunotherapy Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Holding AG Recent Developments/Updates
Table 78. Global Cancer Immunotherapy Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Cancer Immunotherapy Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Cancer Immunotherapy Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Cancer Immunotherapy Drug Production Site of Key Manufacturer
Table 83. Cancer Immunotherapy Drug Market: Company Product Type Footprint
Table 84. Cancer Immunotherapy Drug Market: Company Product Application Footprint
Table 85. Cancer Immunotherapy Drug New Market Entrants and Barriers to Market Entry
Table 86. Cancer Immunotherapy Drug Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Cancer Immunotherapy Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Cancer Immunotherapy Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Cancer Immunotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Cancer Immunotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Cancer Immunotherapy Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Cancer Immunotherapy Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Cancer Immunotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Cancer Immunotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Cancer Immunotherapy Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Cancer Immunotherapy Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Cancer Immunotherapy Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Cancer Immunotherapy Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Cancer Immunotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Cancer Immunotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Cancer Immunotherapy Drug Raw Material
Table 146. Key Manufacturers of Cancer Immunotherapy Drug Raw Materials
Table 147. Cancer Immunotherapy Drug Typical Distributors
Table 148. Cancer Immunotherapy Drug Typical Customers
List of Figures
Figure 1. Cancer Immunotherapy Drug Picture
Figure 2. Global Cancer Immunotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cancer Immunotherapy Drug Consumption Value Market Share by Type in 2022
Figure 4. PD-1 Inhibitor Examples
Figure 5. PDL-1 Inhibitor Examples
Figure 6. T-Cell Stimulant Examples
Figure 7. CTLA Antibody Examples
Figure 8. Global Cancer Immunotherapy Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Cancer Immunotherapy Drug Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Cancer Immunotherapy Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Cancer Immunotherapy Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Cancer Immunotherapy Drug Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Cancer Immunotherapy Drug Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Cancer Immunotherapy Drug Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Cancer Immunotherapy Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Cancer Immunotherapy Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Cancer Immunotherapy Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Cancer Immunotherapy Drug Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Cancer Immunotherapy Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Cancer Immunotherapy Drug Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Cancer Immunotherapy Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 55. China Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Cancer Immunotherapy Drug Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Cancer Immunotherapy Drug Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Cancer Immunotherapy Drug Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Cancer Immunotherapy Drug Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Cancer Immunotherapy Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Cancer Immunotherapy Drug Market Drivers
Figure 76. Cancer Immunotherapy Drug Market Restraints
Figure 77. Cancer Immunotherapy Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug in 2022
Figure 80. Manufacturing Process Analysis of Cancer Immunotherapy Drug
Figure 81. Cancer Immunotherapy Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
